▎药明康德内容团队编辑
图片来源:默沙东官网
参考资料:
[1] FDA Approves Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma. Retrieved December 3, 2021, from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-adjuvant-treatment-stage-iib-or-iic-melanoma
[2] Keytruda Label. Retrieved December 3, 2021, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125514s112lbl.pdf
[3] ADJUVANT IMMUNOTHERAPY PROLONGS RECURRENCE-FREE SURVIVAL IN RESECTED STAGE II B/C MELANOMA [ESMO CONGRESS 2021 PRESS RELEASE]. Retrieved December 3, 2021, from https://www.esmo.org/newsroom/press-office/adjuvant-immunotherapy-prolongs-recurrence-free-survival-in-resected-stage-ii-b-c-melanoma
版权说明:本文来自药明康德内容团队,欢迎个人转发至朋友圈,谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”,获取转载须知。
分享,点赞,在看,聚焦全球生物医药健康创新